Jasper Therapeutics, INC 10-Q quarterly reports

Jasper Therapeutics' Q2 2026 Form 10-Q reveals substantial operating losses and a precarious going concern status, offset by a recent $132 million financing and the acquisition of Kira Pharmaceuticals.

Jasper Therapeutics reports a significant decrease in R&D expenses for Q1 2026, alongside a substantial increase in cash burn, while facing ongoing litigation and substantial doubt about its ability to continue as a going concern.

Jasper Therapeutics reports increased net losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, while investigating efficacy issues in a key clinical trial.

Jasper Therapeutics reports increased net losses and negative cash flow, raising substantial doubt about its ability to continue as a going concern, despite positive clinical data for briquilimab in urticaria.

Jasper Therapeutics reports a net loss of $21.241 million for Q1 2025, focusing on advancing clinical programs targeting mast cell-driven diseases.

Jasper Therapeutics reports a net loss of $18.6 million for the third quarter of 2024, while highlighting progress in clinical trials for its lead product candidate, briquilimab.

Jasper Therapeutics reported a net loss of $28.3 million for the first half of 2024, while advancing its clinical programs for briquilimab.

Jasper Therapeutics reported a net loss of $13.7 million for the first quarter of 2024, but maintains a strong cash position of $118.5 million following a recent underwritten offering.